ArticleInternational journal of biological sciences2026
Young plasma-derived exosomes deliver YOD1 to induce M2 polarization and ameliorate osteoporosis via mTOR signaling pathways.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to evaluate the therapeutic potential of young plasma-derived exosomes (Y-Exos) in osteoporosis, focusing on their capacity to modulate macrophage polarization and bone homeostasis. Ovariectomized (OVX) mice were administered young plasma, aged plasma, exosome-depleted plasma, or plasma-derived exosomes. Bone mass, macrophage polarization, and osteoblast/osteoclast activity were analyzed by micro-CT, flow cytometry, and histology. Human Y-Exos were isolated to examine their direct effects on BMSC osteogenesis and BMM polarization, as well as indirect effects on osteoclastogenesis. Proteomic and transcriptomic approaches were employed to identify key functional proteins and underlying mechanisms. For results, young plasma significantly improved bone mass, increased CD206
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.